Published in
Elsevier, Annals of Oncology, 4(32), p. 488-499, 2021
DOI: 10.1016/j.annonc.2020.12.013
Links
Tools
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
Journal article published in 2020 by
M. Martin,
C. Zielinski,
M. Ruiz-Borrego,
E. Carrasco,
N. Turner,
E. M. Ciruelos,
M. Muñoz,
B. Bermejo,
M. Margeli,
A. Anton,
Z. Kahan,
T. Csöszi,
M. I. Casas,
L. Murillo,
S. Morales 
and other authors.
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 